Brimonidine - An Alpha2-Agonist for Glaucoma
Brimonidine tartrate 0.2% ophthalmic solution (Alphagan - Allergan), a selective alpha2-adrenergic agonist, has been approved by the US Food and Drug Administration (FDA) for treatment of increased intraocular pressure due to open-angle glaucoma or ocular hypertension and for its prevention in patients undergoing argon laser trabeculoplasty....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Brimonidine - An Alpha2-Agonist for Glaucoma
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1002
Article Code: 1002b
Date: June 6, 1997
Volume: 39
Pages: 54-55
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1002
Article Code: 1002b
Date: June 6, 1997
Volume: 39
Pages: 54-55
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)